Department of Pathology and Laboratory Medicine, Women and Infants Hospital, Alpert Medical School of Brown University, Providence, RI, USA.
Clin Chem Lab Med. 2012 Jun;50(6):1003-8. doi: 10.1515/CCLM.2011.671.
The performance of prenatal screening tests for the identification of trisomy 21 (Down syndrome) has markedly improved since the 1970s and early 1980s when maternal age was the sole mode of screening the general pregnant population. With the discovery of second trimester serum markers in the 1980s and 1990s and implementation of double, triple, and quad marker testing; the discovery of first trimester serum and ultrasound markers in the 1990s and implementation of the combined test; and the development of the integrated test and sequential screening strategies over the past decade, the performance of screening has improved to a detection rate of 90%–95% at a false positive rate of 2%–5%. In this review, I will describe the advances in prenatal screening for trisomy 21, present current screening strategies, and discuss guidelines published by professional societies and regulatory bodies, with a focus on current prenatal screening practice in the USA.
自 20 世纪 70 年代和 80 年代初以来,唐氏综合征(Down 综合征)的产前筛查检测性能显著提高,当时母亲年龄是筛查一般孕妇群体的唯一模式。随着 20 世纪 80 年代和 90 年代二、三、四标志物检测的发现,以及第一个二、三、四标志物检测的发现和实施;90 年代的妊娠早期血清和超声标志物以及联合检测的实施;以及过去十年中综合检测和序贯筛查策略的发展,筛查的性能已经提高到假阳性率为 2%至 5%的检测率为 90%至 95%。在这篇综述中,我将描述唐氏综合征产前筛查的进展,介绍当前的筛查策略,并讨论专业协会和监管机构发布的指南,重点是美国当前的产前筛查实践。